These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 27716658)

  • 1. The Diagnostic and Prognostic Value of Neuropsychological Assessment in Memory Clinic Patients.
    Jansen WJ; Handels RL; Visser PJ; Aalten P; Bouwman F; Claassen J; van Domburg P; Hoff E; Hoogmoed J; Leentjens AF; Rikkert MO; Oleksik AM; Smid M; Scheltens P; Wolfs C; Verhey F; Ramakers IH
    J Alzheimers Dis; 2017; 55(2):679-689. PubMed ID: 27716658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Added Prognostic Value of Cerebrospinal Fluid Biomarkers in Predicting Decline in Memory Clinic Patients in a Prospective Cohort.
    Handels RL; Joore MA; Vos SJ; Aalten P; Ramakers IH; Rikkert MO; Scheltens P; Jansen WJ; Visser PJ; van Berckel BM; van Domburg P; Smid M; Hoff E; Hoogmoed J; Bouwman F; Claassen J; Leentjens AF; Wolfs CA; Severens JL; Verhey FR
    J Alzheimers Dis; 2016 Mar; 52(3):875-85. PubMed ID: 27031483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Redefining Amnestic Mild Cognitive Impairment as an Early Form of Alzheimer's Disease Based on Assessment of Memory Systems.
    Bolívar JC; Saladie DG
    J Alzheimers Dis; 2016 May; 53(2):705-12. PubMed ID: 27163821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?
    Visser PJ; Scheltens P; Verhey FR
    J Neurol Neurosurg Psychiatry; 2005 Oct; 76(10):1348-54. PubMed ID: 16170074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.
    Visser PJ; Verhey F; Knol DL; Scheltens P; Wahlund LO; Freund-Levi Y; Tsolaki M; Minthon L; Wallin AK; Hampel H; Bürger K; Pirttila T; Soininen H; Rikkert MO; Verbeek MM; Spiru L; Blennow K
    Lancet Neurol; 2009 Jul; 8(7):619-27. PubMed ID: 19523877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating Biomarkers for Underlying Alzheimer's Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers.
    Rhodius-Meester HF; Koikkalainen J; Mattila J; Teunissen CE; Barkhof F; Lemstra AW; Scheltens P; Lötjönen J; van der Flier WM
    J Alzheimers Dis; 2016; 50(1):261-70. PubMed ID: 26577521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Responsiveness of magnetic resonance imaging and neuropsychological assessment in memory clinic patients.
    Schmand B; Rienstra A; Tamminga H; Richard E; van Gool WA; Caan MW; Majoie CB
    J Alzheimers Dis; 2014; 40(2):409-18. PubMed ID: 24473187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How does additional diagnostic testing influence the initial diagnosis in patients with cognitive complaints in a memory clinic setting?
    Meijs AP; Claassen JA; Rikkert MG; Schalk BW; Meulenbroek O; Kessels RP; Melis RJ
    Age Ageing; 2015 Jan; 44(1):72-7. PubMed ID: 24847028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and clinical significance of epileptiform EEG discharges in a large memory clinic cohort.
    Liedorp M; Stam CJ; van der Flier WM; Pijnenburg YA; Scheltens P
    Dement Geriatr Cogn Disord; 2010; 29(5):432-7. PubMed ID: 20502017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Markers of Alzheimer's disease in a population attending a memory clinic.
    Frisoni GB; Prestia A; Zanetti O; Galluzzi S; Romano M; Cotelli M; Gennarelli M; Binetti G; Bocchio L; Paghera B; Amicucci G; Bonetti M; Benussi L; Ghidoni R; Geroldi C
    Alzheimers Dement; 2009 Jul; 5(4):307-17. PubMed ID: 19560101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medial temporal atrophy but not memory deficit predicts progression to dementia in patients with mild cognitive impairment.
    Geroldi C; Rossi R; Calvagna C; Testa C; Bresciani L; Binetti G; Zanetti O; Frisoni GB
    J Neurol Neurosurg Psychiatry; 2006 Nov; 77(11):1219-22. PubMed ID: 16891386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Memory evaluation with a new cued recall test in patients with mild cognitive impairment and Alzheimer's disease.
    Ivanoiu A; Adam S; Van der Linden M; Salmon E; Juillerat AC; Mulligan R; Seron X
    J Neurol; 2005 Jan; 252(1):47-55. PubMed ID: 15654553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Japanese version of the Test Your Memory as a screening test in a Japanese memory clinic.
    Hanyu H; Maezono M; Sakurai H; Kume K; Kanetaka H; Iwamoto T
    Psychiatry Res; 2011 Nov; 190(1):145-8. PubMed ID: 21570726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion of amnestic Mild Cognitive Impairment to dementia of Alzheimer type is independent to memory deterioration.
    Rozzini L; Chilovi BV; Conti M; Bertoletti E; Delrio I; Trabucchi M; Padovani A
    Int J Geriatr Psychiatry; 2007 Dec; 22(12):1217-22. PubMed ID: 17562522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid-β oligomers relate to cognitive decline in Alzheimer's disease.
    Jongbloed W; Bruggink KA; Kester MI; Visser PJ; Scheltens P; Blankenstein MA; Verbeek MM; Teunissen CE; Veerhuis R
    J Alzheimers Dis; 2015; 45(1):35-43. PubMed ID: 25547634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment.
    Chételat G; Eustache F; Viader F; De La Sayette V; Pélerin A; Mézenge F; Hannequin D; Dupuy B; Baron JC; Desgranges B
    Neurocase; 2005 Feb; 11(1):14-25. PubMed ID: 15804920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Subjective cognitive impairment and Alzheimer's disease: a two year follow up of 51 subjects during two years].
    Sambuchi N; Muraccioli I; Alescio-Lautier B; Paban V; Sambuc R; Jouve É; Geda YE; Petersen RK; Michel BF
    Geriatr Psychol Neuropsychiatr Vieil; 2015 Dec; 13(4):462-71. PubMed ID: 26707564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical AD predicts decline in memory and executive functions in subjective complaints.
    van Harten AC; Smits LL; Teunissen CE; Visser PJ; Koene T; Blankenstein MA; Scheltens P; van der Flier WM
    Neurology; 2013 Oct; 81(16):1409-16. PubMed ID: 24049134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aβ and cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease.
    Lim YY; Maruff P; Pietrzak RH; Ellis KA; Darby D; Ames D; Harrington K; Martins RN; Masters CL; Szoeke C; Savage G; Villemagne VL; Rowe CC;
    Alzheimers Dement; 2014 Nov; 10(6):743-751.e1. PubMed ID: 24589436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.